IGEA Pharma N.V.

LSE:0AAX Stock Report

Market Cap: CHF 1.7m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IGEA Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0AAX?
Owner TypeNumber of SharesOwnership Percentage
Institutions170,1140.0505%
General Public31,814,5769.44%
Private Companies73,511,89321.8%
Individual Insiders231,533,55968.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 12 shareholders own 90.56% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
30.3%
Gerardo Caradonna
101,944,500CHF 509.7k0%no data
15.9%
Andrea Ivancevich
53,649,900CHF 268.2k0%no data
13.4%
Anna Loraschi
45,000,000CHF 225.0k0%no data
9.11%
Blue Sky Angel Lab Srl
30,690,000CHF 153.4k0%no data
7.07%
All Asset Management S.A.
23,821,893CHF 119.1k7,890%no data
5.64%
C.H.I. B.V.
19,000,000CHF 95.0k0%no data
4.6%
Cristina Canepa
15,500,000CHF 77.5k812%no data
4.34%
Michele Muller
14,629,159CHF 73.1k0%no data
0.18%
Rosanna Squitti
600,000CHF 3.0k0%no data
0.059%
Francesco Patrocollo
200,000CHF 1.0k0%no data
0.05%
Negma Group Ltd.
170,114CHF 850.50%0.2%
0.003%
Vinvcenzo Moccia
10,000CHF 50.00%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/07/24 14:25
End of Day Share Price 2023/04/26 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IGEA Pharma N.V. is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthias GreiffenbergerGBC AG